Events & Presentations

Date	Documents
March 6, 2024	Corporate Presentation - March 2024

Archived Investor Events and Presentations

Archived Scientific Presentations

Date	Documents
March 6, 2024	Vudalimab (PD-1 x CTLA-4) Monotherapy in mCRPC - Clinical Update with Additional Data
November 3, 2023	SITC 2023: Synergistic targeting of multiple activating pathways with natural killer cell engagers
November 3, 2023	SITC 2023: A phase 1, first-in-human, open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors
November 3, 2023	SITC 2023: Optimally engineered IL18 Fc-fusion protein balance potency and pharmacokinetics to promote strong anti-tumor activity
May 30, 2023	EULAR 2023: XmAb564, a Novel Potency-Tuned IL-2 Fc-Fusion Protein, Selectively Expands Regulatory T Cells: Results from a Single Ascending-Dose Study in Healthy Adult Volunteers
April 17, 2023	AACR 2023: Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
December 12, 2022	ASH 2022: A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
November 10, 2022	LAG3-targeted IL15/IL15Rα-Fc (LAG3 x IL15) fusion proteins for preferential TIL expansion via cis delivery of IL15 to LAG3+ cells
November 10, 2022	A Phase 2 Study of Vudalimab, a PD-1 × CTLA-4 Bispecific Antibody, Plus Chemotherapy or Targeted Therapy in Patients With Molecularly Defined Subtypes of Metastatic Castration-Resistant Prostate Cancer
November 10, 2022	Synergistic combination of Natural Killer cell Engagers (NKEs) with proinflammatory cytokines
November 10, 2022	A Phase 2 Study of Vudalimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
November 10, 2022	SITC 2022: XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP
November 10, 2022	Costimulatory CD28 trispecific antibodies targeting PDL1 and/or PDL2 enhance T cell activation in solid tumors
November 10, 2022	A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Patients With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
November 7, 2022	XmAb564 (IL-2-Fc): Single Dose Phase 1a Data Presentation
June 5, 2022	ASCO 2022: A Phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3)
April 8, 2022	AACR 2022: Engineered IL18 heterodimeric Fc-fusions featuring improved stability, reduced potency, and insensitivity to IL18BP
April 8, 2022	AACR 2022: LAG3-targeted IL15/IL15Rα-Fc (LAG3 x IL15) fusion proteins for preferential TIL expansion
December 12, 2021	Phase 1 Safety and Anti-tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma
November 12, 2021	SITC 2021: PD1 x TGFβR2 and CD5 x TGFβR2 bispecifics selectively block TGFβR2 on target-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors
November 12, 2021	SITC 2021: IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents
November 12, 2021	SITC 2021: Natural killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines
November 12, 2021	SITC 2021: PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
November 12, 2021	SITC 2021: Preliminary Clinical Experience With Vudalimab, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
April 10, 2021	IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents
April 10, 2021	PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
April 10, 2021	Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells
April 10, 2021	Affinity tuned XmAb® 2+1 GPC3 x CD3 bispecific antibodies demonstrate selective activity in liver cancer models
November 9, 2020	Preliminary Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of XmAb®20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
November 9, 2020	Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
November 9, 2020	PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors
November 9, 2020	Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
June 22, 2020	AACR 2020: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models
June 22, 2020	AACR 2020: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity
June 22, 2020	AACR 2020: Affinity tuned XmAb® 2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells
June 22, 2020	AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies
December 9, 2019	ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL
March 4, 2019	Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format
December 3, 2018	ASH 2018: Regulatory T cell selective IL-2-Fc fusion proteins for the treatment of autoimmune diseases
November 9, 2018	SITC 2018: An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure
November 9, 2018	SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation
April 18, 2018	AACR 2018: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure
April 16, 2018	AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation
November 13, 2017	SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T CellActivation and Proliferation
November 13, 2017	SITC 2017: Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation
April 4, 2017	AACR 2017: IL 15/IL 15Ra; heterodimeric Fc-fusions with extended half-lives
April 4, 2017	AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation
November 9, 2016	2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation
November 9, 2016	2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation
December 7, 2014	American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111

Tools

Events & Presentations

Upcoming Events

Archived Investor Events and Presentations

Archived Scientific Presentations